P2.01-33 Open-Label, Biomarker-Directed Platform Study in NSCLC Patients Who Progressed on an Anti-Pd-(L)1 Containing Therapy (HUDSON)

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.1087

Related search